US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
HV

HVO.L

$6.60
Sharia status
NOT COMPLIANT
Per In-house ratio engine · assessed 2026-08-27
HTR non-permissible income 1.95%
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

hVIVO plc (HVO.L) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

Market & analysts
Price target
$15.94
+141.5% · 8 analysts
Institutional own.
30.6%
of shares
NON-COMPLIANT
Sharia compliance
1.95%
Non-permissible income — HTR, from filings (2025-12-31)
$15.94
Price target (+141.5%) · 8 analysts
30.6%
Institutional ownership

🕌 In-house Compliance Research

Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. HVO.L files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail

RatioValueThresholdResult
Interest-bearing debt 62.90% 30.00% Fail
Interest-bearing investments 30.41% 30.00% Fail
Non-permissible income 1.95% 5.00% Pass

Usmani Fail

RatioValueThresholdResult
Interest-bearing debt 41.18% 33.00% Fail
Interest-bearing investments 19.91% 33.00% Pass
Non-liquid assets 71.27% at least 20.00% Pass
Non-permissible income 1.95% 5.00% Pass

MSCI Pass

RatioValueThresholdResult
Interest-bearing debt 41.18% 33.33% Fail
Cash + interest-bearing securities 19.91% 33.33% Pass
Accounts receivable 28.73% 33.33% Pass
Non-permissible income 1.95% 5.00% Pass

FTSE Pass

RatioValueThresholdResult
Interest-bearing debt 41.18% 33.33% Fail
Cash + interest-bearing securities 19.91% 33.33% Pass
Accounts receivable 28.73% 50.00% Pass
Non-permissible income 1.95% 5.00% Pass

Dow Jones Islamic Market Fail

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 33.88% 33.00% Fail
Cash + interest-bearing securities 16.38% 33.00% Pass
Accounts receivable 7.25% 33.00% Pass
Non-permissible income 1.95% 5.00% Pass

S&P Shariah Pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 24.99% 33.00% Pass
Cash + interest-bearing securities 12.08% 49.00% Pass
Accounts receivable 5.35% 49.00% Pass
Non-permissible income 1.95% 5.00% Pass

MSCI M-Series Pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 24.99% 33.33% Pass
Cash + interest-bearing securities 12.08% 33.33% Pass
Accounts receivable 17.43% 49.00% Pass
Non-permissible income 1.95% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

9.888.567.245.914.592025-09-112026-03-122026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
6.20
S2
6.35
S1
6.50
PIVOT
6.65
R1
6.80
R2
6.95
R3
7.10

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
6.10193 7.69807
±11.57% from 6.9, made 2026-09-04 · resolves 2026-09-11
BUY
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22072 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)43.40NEUTRAL
Stochastic %K (14)25.00NEUTRAL
CCI (20)-24.45NEUTRAL
Williams %R (14)-75.00NEUTRAL
MACD (12,26,9)0.01BUY
ROC (10)1.54BUY
Momentum (10)0.10BUY
EMA (10)6.75SELL
SMA (10)6.81SELL
EMA (20)6.76SELL
SMA (20)6.68SELL
EMA (30)6.80SELL
SMA (30)6.77SELL
EMA (50)6.92SELL
SMA (50)6.85SELL
EMA (100)7.13SELL
SMA (100)7.33SELL
EMA (200)7.08SELL
SMA (200)7.15SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About hVIVO plc

Healthcare · Diagnostics & Research

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company also provides clinical research services, including early-phase trials and human pharmacological studies. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

hvivo.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Not enough price history yet for a smart-money structure read on any timeframe.

Momentum & Volume

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.